Side-by-side · Research reference
LiraglutidevsMT-1
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedFlagship14/45 cited
BFDA-ApprovedHUMAN-REVIEWED9/51 cited
Liraglutide
Daily GLP-1 RA · FDA-Approved
SQ · Abdomen / thigh / arm · Once daily
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
01Mechanism of Action
Parameter
Liraglutide
MT-1
Primary target
GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
Pathway
GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014Marso 2016
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Downstream effect
Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Feedback intact?
Glucose-dependent insulin release preserves physiological feedback
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Origin
Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Antibody development
—
—
02Dosage Protocols
Parameter
Liraglutide
MT-1
Standard dose (weight, Saxenda)
3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014
—
Frequency
Once daily, same time each day
Every 60 days
Sustained release implant — no daily administration required.
Titration schedule
0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks
Mitigates GI side effects.
—
Evidence basis
FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016SAXENDA (liraglutide) injectio 2014
Phase 3 RCT / FDA-approved orphan drug
Duration
Indefinite for chronic indication
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
Reconstitution
Pre-filled commercial pen (no reconstitution)
—
Timing
Any time of day; consistent
—
Standard dose
—
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
Indication
—
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
Route
—
Subcutaneous implant — upper arm or abdomen
Stability
—
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
04Side Effects & Safety
Parameter
Liraglutide
MT-1
GI symptoms
Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014
—
Pancreatitis risk
Rare; discontinue if suspected
—
Thyroid C-cell tumours
Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014
—
Hypoglycemia
Low risk as monotherapy; elevated with sulfonylureas / insulin
—
Heart rate
Modest ↑ resting HR (~2-3 bpm)
—
Pregnancy / OB
Contraindicated
—
Nausea
—
Common (>10%) — mild, transient
Implant site reaction
—
Erythema, bruising, tenderness at insertion site
Hyperpigmentation
—
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
Melanocytic changes
—
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
Headache
—
Occasional (MC1R-independent melanocortin effects)
Photosensitivity (paradoxical)
—
Rare phototoxic reactions despite melanin increase
Contamination risk (unregulated)
—
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
Absolute Contraindications
Liraglutide
- ·MTC personal or family history; MEN2
- ·Pregnancy / breastfeeding
- ·Hypersensitivity to liraglutide
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Relative Contraindications
Liraglutide
- ·Severe gastroparesis
- ·History of pancreatitis
- ·Severe gastrointestinal disease
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
05Administration Protocol
Parameter
Liraglutide
MT-1
1. Reconstitution / device
Commercial pre-filled pen, no reconstitution required.
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
2. Injection site
SQ — abdomen, thigh, or upper arm. Rotate sites.
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
3. Timing
Once daily, same time each day. Take with or without food.
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
4. Storage
Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
5. Needle
Pen-supplied 32G needle.
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.